Discovery

Weill Cornell Medicine receives USD 3.25m NIH award for AAV gene therapy Alzheimer's trial

Edited by Robert McTiernan··4 min read

Weill Cornell Medicine has received a USD 3.25 million UG3 award from the National Institute on Aging to advance an AAV-mediated gene therapy into Phase I human testing in APOE4 homozygous patients with early Alzheimer's disease, one of the more targeted clinical-stage research funding awards to emerge from NIH grants 2026 allocations in neurodegeneration.

Principal investigator Ronald G. Crystal and his team at Weill Medical College of Cornell University will use the UG3 activity code funding — structured as a milestone-gated mechanism that conditions a subsequent UH3 award on Phase IA completion — to conduct a dose-ranging safety trial of AAVrh.10hAPOE2Ch, an adeno-associated virus vector engineered to deliver a modified form of the protective APOE2 allele carrying the Christchurch mutation (R136S) directly into the central nervous system via cerebrospinal fluid administration.

Grant specifics

The scientific rationale draws on the observation that APOE2 offsets the pathological effects of APOE4 in heterozygous carriers, and that the Christchurch variant — a gain-of-function allele documented in a Colombian kindred with PSEN1-linked early onset Alzheimer's disease — confers protection against tau pathology beyond what unmodified APOE2 provides. Preclinical work in two humanized APOE4 mouse strains, one modeling amyloid accumulation and one tau pathology, showed the E2Ch construct outperformed unmodified E2 across both pathological readouts, providing the translational basis for the IND filing and trial initiation activities funded under this award.

The Phase IA component, covered by the UG3 portion of the grant, will enroll three participants per dose cohort across five half-log incremental dose levels ranging from 5.7 x 10¹² to 5.7 x 10¹⁴ total genome copies, administered intrathecally via C1-C2 puncture. The primary endpoint is safety and identification of the highest tolerable dose. Secondary endpoints include preliminary biomarker assessments and measurement of CSF APOE2Ch levels. Regulatory activities — including FDA IND clearance, IRB approval, biosafety review, and DSMB establishment — are incorporated into the UG3 scope alongside clinical-grade vector manufacturing.

The subsequent Phase IB study, structured under the UH3 continuation, would enroll ten APOE4 homozygous patients with early Alzheimer's disease at the dose selected from Phase IA. That cohort would undergo a biomarker-dense assessment protocol including amyloid and tau PET imaging, CSF quantification of Aβ42, Aβ40, total tau, phospho-tau, GFAP, and NfL, MRI volumetrics, cognitive testing, and target engagement measurement via CSF-derived APOE heparin binding. The structure reflects a growing pattern in aging research grants where federal research funding is used to de-risk gene therapy assets through rigorous early-phase biomarker characterization before broader efficacy trials are considered.

The AllSci BriefSystematic R&D and deal news. Daily.

The award runs from April 2026 through March 2028, with the current FY2026 budget period accounting for USD 1,961,834 in direct costs and USD 1,290,900 in indirect costs against the USD 3,252,734 total. The grant was issued April 1, 2026 and is listed as a new, active award on NIH RePORTER under project number 1UG3AG098024-01. It was reviewed by a Special Emphasis Panel within the NIA's study section structure, consistent with the agency's practice of convening targeted panels for gene therapy and neurodegeneration submissions that fall outside standard standing study sections.

Research context

The APOE4 homozygous population represents a genetically defined subgroup carrying substantially elevated lifetime risk for Alzheimer's disease relative to APOE3 carriers, and the absence of approved disease-modifying therapies specifically developed for this genotype has drawn attention from both academic and commercial sponsors. The NIA's decision to fund a Phase I trial in this population through the UG3/UH3 mechanism — a structure designed to support translational research that requires staged regulatory and manufacturing milestones before human dosing — reflects the agency's interest in moving CNS gene therapy candidates from preclinical validation into human safety data generation within a defined federal research funding framework.

Crystal's laboratory at Weill Cornell has a documented history in AAV-based gene transfer, and the use of the AAVrh.10 capsid — selected for its neurotropic properties — is consistent with the group's prior work in CNS-directed vector delivery. The Christchurch modification layered onto the APOE2 backbone represents an attempt to engineer a more durable protective signal than the naturally occurring allele alone, a strategy that distinguishes this program from earlier APOE2 gene therapy approaches that have been explored in the field.

Spot something wrong? Report an issue with this article